The estimated Net Worth of Robert P Lenk is at least $40.1 Thousand dollars as of 8 May 2024. Robert Lenk owns over 4,167 units of Plus Therapeutics stock worth over $39,591 and over the last 17 years he sold PSTV stock worth over $465. In addition, he makes $0 as Independent Director at Plus Therapeutics.
Robert has made over 8 trades of the Plus Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 4,167 units of PSTV stock worth $8,501 on 8 May 2024.
The largest trade he's ever made was buying 9,199 units of Plus Therapeutics stock on 8 November 2023 worth over $14,902. On average, Robert trades about 3,097 units every 104 days since 2008. As of 8 May 2024 he still owns at least 29,327 units of Plus Therapeutics stock.
You can see the complete history of Robert Lenk stock trades at the bottom of the page.
Dr. Robert P. Lenk Ph.D. has been appointed as Independent Director of the Company effective 4/1/2020. Dr. Lenk is President of Link Pharmaceuticals, a pharmaceuticals development consultant to multinational corporations and startups. Previously, Dr. Lenk has served as Chief Scientific Officer of MediVector, Inc.; President of the NanoWorks division of Luna Innovations, Inc.; President & CEO of Therapeutics 2000, Inc.; and Vice President of Research & Development at Argus Pharmaceuticals. Dr. Lenk was also a Cofounder of The Liposome Co. and a Staff Fellow of the National Institute of Child Health and Human Development. Dr. Lenk has a PhD and BS from the Massachusetts Institute of Technology.
Robert Lenk is 69, he's been the Independent Director of Plus Therapeutics since 2020. There are 2 older and 11 younger executives at Plus Therapeutics. The oldest executive at Plus Therapeutics, Inc. is Dr. Norman D. LaFrance FACNP, FACP, M.D., 73, who is the Chief Medical Officer & Sr. VP.
Robert's mailing address filed with the SEC is C/O PLUS THERAPEUTICS INC., 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN, TX, 78756.
Over the last 5 years, insiders at Plus Therapeutics have traded over $4,518 worth of Plus Therapeutics stock and bought 251,584 units worth $410,360 . The most active insiders traders include Greg Petersen, Marc H Hedrick, and Richard J Hawkins. On average, Plus Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $8,201. The most recent stock trade was executed by Marc H Hedrick on 10 September 2024, trading 8,000 units of PSTV stock currently worth $9,840.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Plus Therapeutics executives and other stock owners filed with the SEC include: